XASE · Healthcare · Biotechnology
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q3 2026 | -0.09 | -0.09 | +0.00% | $0 | ➖ Inline | +1.15% | +10.81% | — |
| 2026-02-17 | Q2 2026 | -0.10 | -0.11 | -10.00% | $0 | ❌ Miss | -5.73% | +0.97% | +1.94% |
| 2025-11-14 |
| Q1 2026 |
| -0.16 |
| -0.10 |
| +37.50% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-09-29 | Q4 2025 | — | -0.13 | — | $0 | — | — | — | — |
| 2025-02-14 | Q2 2025 | — | -0.14 | — | $0 | — | +0.00% | +11.11% | -2.96% |
| 2024-11-14 | Q1 2025 | — | -0.23 | — | $0 | — | -8.21% | -4.48% | +10.45% |
| 2024-09-27 | Q4 2024 | — | -0.19 | — | $0 | — | +3.45% | +1.38% | +4.83% |
| 2024-05-15 | Q3 2024 | -0.19 | -0.16 | +15.79% | $0 | ✅ Beat | +23.89% | +26.11% | +5.56% |
Showing last 8 quarters.